Richard P Ramonell1, Imran H Iftikhar2. 1. Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Department of Medicine, Emory University School of Medicine, 613 Michael St, NE, Atlanta, GA, USA. 2. Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Department of Medicine, Emory University School of Medicine, 613 Michael St, NE, Atlanta, GA, USA. imran.hasan.iftikhar@emory.edu.
Abstract
BACKGROUND: Several new treatments for severe asthma have become available in the last decade; yet, little data exist to guide their use in specific patient populations. OBJECTIVE: A network meta-analysis was conducted comparing the efficacy of FDA-approved monoclonal antibody therapies in preventing exacerbations in patients with severe eosinophilic asthma. METHODS: PubMed and Ovid were searched from inception until July 2019 for randomized controlled trials that studied the efficacy of benralizumab, dupilumab, mepolizumab, and reslizumab, in preventing acute exacerbations of asthma. Studies were included if they reported data for patients with severe eosinophilic asthma (defined in this meta-analysis as absolute eosinophil count ≥ 250 cells/μL). Annualized rate ratios for asthma exacerbations (during treatment) were calculated and converted to log rate ratios. Direct and indirect treatment estimates (for inter-drug differences) were analyzed using frequentist network meta-analysis methodology in R and treatments were ranked based on P-scores. RESULTS: In total, nine studies were included in the final analysis. Network meta-analysis revealed that all drugs were superior to placebo in preventing rates of asthma exacerbation in the study population and no inter-drug differences existed. Dupilumab was found to have the greatest magnitudes of effect on decreasing log rate ratio of asthma exacerbation based on P-score (0.83). CONCLUSION: Benralizumab, dupilumab, mepolizumab, and reslizumab are all associated with decreased asthma exacerbations in patients with eosinophilic asthma, with no significant inter-drug differences.
BACKGROUND: Several new treatments for severe asthma have become available in the last decade; yet, little data exist to guide their use in specific patient populations. OBJECTIVE: A network meta-analysis was conducted comparing the efficacy of FDA-approved monoclonal antibody therapies in preventing exacerbations in patients with severe eosinophilic asthma. METHODS: PubMed and Ovid were searched from inception until July 2019 for randomized controlled trials that studied the efficacy of benralizumab, dupilumab, mepolizumab, and reslizumab, in preventing acute exacerbations of asthma. Studies were included if they reported data for patients with severe eosinophilic asthma (defined in this meta-analysis as absolute eosinophil count ≥ 250 cells/μL). Annualized rate ratios for asthma exacerbations (during treatment) were calculated and converted to log rate ratios. Direct and indirect treatment estimates (for inter-drug differences) were analyzed using frequentist network meta-analysis methodology in R and treatments were ranked based on P-scores. RESULTS: In total, nine studies were included in the final analysis. Network meta-analysis revealed that all drugs were superior to placebo in preventing rates of asthma exacerbation in the study population and no inter-drug differences existed. Dupilumab was found to have the greatest magnitudes of effect on decreasing log rate ratio of asthma exacerbation based on P-score (0.83). CONCLUSION: Benralizumab, dupilumab, mepolizumab, and reslizumab are all associated with decreased asthma exacerbations in patients with eosinophilic asthma, with no significant inter-drug differences.
Authors: W Busse; J Corren; B Q Lanier; M McAlary; A Fowler-Taylor; G D Cioppa; A van As; N Gupta Journal: J Allergy Clin Immunol Date: 2001-08 Impact factor: 10.793
Authors: Klaus F Rabe; Parameswaran Nair; Guy Brusselle; Jorge F Maspero; Mario Castro; Lawrence Sher; Hongjie Zhu; Jennifer D Hamilton; Brian N Swanson; Asif Khan; Jingdong Chao; Heribert Staudinger; Gianluca Pirozzi; Christian Antoni; Nikhil Amin; Marcella Ruddy; Bolanle Akinlade; Neil M H Graham; Neil Stahl; George D Yancopoulos; Ariel Teper Journal: N Engl J Med Date: 2018-05-21 Impact factor: 91.245
Authors: Richard M Nowak; Joseph M Parker; Robert A Silverman; Brian H Rowe; Howard Smithline; Faiz Khan; Jon P Fiening; Keunpyo Kim; Nestor A Molfino Journal: Am J Emerg Med Date: 2014-10-05 Impact factor: 2.469
Authors: S T Holgate; A G Chuchalin; J Hébert; J Lötvall; G B Persson; K F Chung; J Bousquet; H A Kerstjens; H Fox; J Thirlwell; G Della Cioppa Journal: Clin Exp Allergy Date: 2004-04 Impact factor: 5.018
Authors: Sally Wenzel; Mario Castro; Jonathan Corren; Jorge Maspero; Lin Wang; Bingzhi Zhang; Gianluca Pirozzi; E Rand Sutherland; Robert R Evans; Vijay N Joish; Laurent Eckert; Neil M H Graham; Neil Stahl; George D Yancopoulos; Mariana Louis-Tisserand; Ariel Teper Journal: Lancet Date: 2016-04-27 Impact factor: 79.321
Authors: Andrew N Menzies-Gow; Claire McBrien; Bindhu Unni; Celeste M Porsbjerg; Mona Al-Ahmad; Christopher S Ambrose; Karin Dahl Assing; Anna von Bülow; John Busby; Borja G Cosio; J Mark FitzGerald; Esther Garcia Gil; Susanne Hansen; Liam G aHeaney; Mark Hew; David J Jackson; Maria Kallieri; Stelios Loukides; Njira L Lugogo; Andriana I Papaioannou; Désirée Larenas-Linnemann; Wendy C Moore; Luis A Perez-de-Llano; Linda M Rasmussen; Johannes M Schmid; Salman Siddiqui; Marianna Alacqua; Trung N Tran; Charlotte Suppli Ulrik; John W Upham; Eileen Wang; Lakmini Bulathsinhala; Victoria A Carter; Isha Chaudhry; Neva Eleangovan; Ruth B Murray; Chris A Price; David B Price Journal: J Asthma Allergy Date: 2022-01-13